Loading provider…
Loading provider…
Medical Oncology Physician in Duarte, CA
NPI: 1417050998HQ Phone
Get MD Mihaela's Phone Numberphone_androidMobile
Get MD Mihaela's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
NC State Medical License
2000
CA State Medical License
2004 - 2026
FL State Medical License
1999 - 2006
MI State Medical License
1997 - 1998

American Board of Internal Medicine
Medical Oncology
University of Florida College of Medicine Jacksonville
Fellowship • Hematology and Medical Oncology
1998 - 2000
Rutgers Health/Monmouth Medical Center
Residency • Internal Medicine
1995 - 1998
University of Medicine and Pharmacy ‘Gr T Popa” Iasi
Medical School
Until 1992
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86).
Authors: Angela Jain, Gini Fleming, Daniela Matei
Publication Date: 2019-08-11
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receivi...
Authors: Joyce F Liu, Niya Xiong, Robert M Wenham, Andrea Wahner-Hendrickson, Deborah K Armstrong
Phase I of fixed-dose-rate gemcitabine in combination with bortezomib in patients with advanced solid tumors.
Authors: Thehang Luu, George Somlo
Publication Date: 2008-05
Lead Sponsor: PACT Pharma, Inc.
Intervention / Treatment: BIOLOGICAL: IL-2, BIOLOGICAL: NeoTCR-P1 adoptive cell therapy, BIOLOGICAL: nivolumab
Lead Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: BIOLOGICAL: Pembrolizumab, BIOLOGICAL: Modified Vaccinia Virus Ankara Vaccine Expressing p53
Lead Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, OTHER: Pharmacological Study, DRUG: Gemcitabine Hydrochloride, DRUG: Gemcitabine, BIOLOGICAL: Mirvetuximab Soravtansine